YAbS







Distribution of general development status category
Distribution of General Molecular
Category
Distribution of primary therapeutic
area
Distribution of
Targets

Click here to filter based on above criteria:


Showing entries from 71 to 80 of 480
Show records
Record category Entry ID INN Brand name Format, general category Target(s) Isotype (Fc) Light chain isotype Most advanced stage of development Status Primary therapeutic area
Approved YABS0071 Tafolecimab SINTBILO Full length Ab PCSK9 IgG2 kappa Approved China Active Metabolic disorders
Approved YABS0072 Sintilimab Tyvyt Full length Ab PD-1 IgG4 kappa Approved China Active Cancer
Approved YABS0073 Rituximab Rituxan Full length Ab CD20 IgG1 kappa Approved EU, US, Japan, Australia Active Cancer
Approved YABS0074 Ibritumomab tiuxetan Zevalin Full length Ab conjugate CD20 IgG1 kappa Approved EU, US, Japan Active Cancer
Approved YABS0075 Ramucirumab Cyramza Full length Ab VEGFR2 IgG1 kappa Approved EU, US, Japan, Australia Active Cancer
Approved YABS0076 Necitumumab Portrazza Full length Ab EGFR IgG1 kappa Approved EU, US, Japan Active Cancer
Approved YABS0077 Cetuximab Erbitux Full length Ab EGFR IgG1 kappa Approved EU, US, Japan, Australia Active Cancer
Approved YABS0078 Tebentafusp KIMMTRAK Fragment fusion CD3, gp100 None TBD Approved EU, US, Canada, UK, Australia Active Cancer
Approved YABS0079 Mirvetuximab soravtansine ELAHERE Full length Ab conjugate FR alpha IgG1 kappa Approved EU, US Active Cancer
Approved YABS0080 Sacituzumab govitecan Trodelvy  Full length Ab conjugate TROP-2 IgG1 kappa Approved EU, US, Australia Active Cancer